Meta: In July of 2025, the U.S. Food and Drug Administration approved various anti-cancer treatments and therapeutic ...

The French pharmaceutical company claims that Sarclisa-VRD showed great improvement in the minimum residual disease (MRD) ...

FDA granted Orphan Drug Designation to Sanofi’s SAR446523, a monoclonal antibody targeting GPRC5D, for relapsed/refractory ...

A Chester man is back home Friday night with quite a story to tell. Steve Joseph captained his 26-foot Boston Whaler over ...

Since 2009, the UPMC Hillman Academy has been giving high school and college students a chance to learn and research.

Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

As new research spotlights the obesity-cancer connection, experts warn we’ve underestimated just how much excess weight – and the complex biology behind it – can fuel the disease.

The RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of the RSU award is ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Bristol-Myers Squibb Company beats revenue forecasts & raises 2025 guidance. Click for key BMY catalysts, risks, and outlook ...

Canine and human cancers bear many similarities — studies in dogs are helping to develop treatments for both species.